Warning Letter Counts Are a Bad Risk Ranking

what do the raw counts actually return per search term?

The raw counts run from 5 to 146 depending on the exact word you search, and we reproduced every number below on 2026-08-07 by reading the total_items field on FDA's own warning letter search results. Search 'fat burner' and the database returns 5 letters. Search 'diabetes' instead and it returns 146 — a 29-fold difference between two search terms that both, in theory, point at the same weight-and-metabolism supplement market.

Nine search terms, nine different denominators.

why does searching a product name like 'fat burner' undercount a whole vertical?

'Fat burner' undercounts the metabolism vertical because it searches a marketing label, not the claim language FDA actually cites when it writes a letter. FDA's investigators quote the disease claim on the page — a symptom cluster, a named condition like diabetes or hypothyroidism, a mechanism such as insulin resistance or thyroid hormone conversion — and the product's category name is usually just one line inside a much longer citation, if it appears at all. A brand that calls its capsule a 'metabolism booster,' a 'thermogenic,' a 'weight-loss support formula,' or simply names it after an ingredient will never trigger a 'fat burner' match in FDA's search box, even when the letter it received cites a claim built on exactly the mechanism the search term was supposed to catch.

The same trap catches any product-category label searched instead of the regulatory vocabulary underneath it. 'Probiotic' undercounts gut-health disease claims the same way 'joint supplement' undercounts arthritis claims: the label sells the product, the letter cites the disease.

do these counts separate supplements from drugs and devices?

No — every count above spans all FDA-regulated product types, not supplements alone. A search for 'cholesterol' or 'diabetes' returns prescription-drug manufacturing letters and medical-device labeling citations right alongside dietary supplement misbranding letters, because FDA's search tool doesn't offer a category filter limiting results to supplements.

The word 'supplement' is not a filter FDA offers.

We did not open all 251 diabetes- and cholesterol-search results to hand-sort supplement letters from drug and device letters — that's a manual read of every record, not a search query, and it's the one number on this page we could not independently confirm. Reading each letter's product classification line by line is what would settle it.

which office issued the letters, and does that change how you read them?

Yes — the letters split across at least two FDA centers, and knowing which one signed a letter tells you whether you're looking at a labeling problem or a manufacturing one. FDA's Center for Food Safety and Applied Nutrition, CFSAN, writes the disease-claim letters that dominate the diabetes and cholesterol counts: the ten letters CFSAN issued in a single day on September 7, 2021, all charged 'Unapproved New Drugs/Misbranded,' account for a meaningful slice of the diabetes count by themselves. CFSAN ran the same play again on November 14, 2022, sending five same-day cholesterol letters to iwi, BergaMet, Essential Elements, Chambers' Apothecary and Anabolic Laboratories.

FDA's Center for Drug Evaluation and Research, CDER, writes a different kind of letter for a different kind of product. Its March 2026 letter to peptide seller Gram Peptides charges unapproved-new-drug violations for injectable research peptides — a manufacturing and distribution theory, not the labeling misbranding theory CFSAN builds from symptom language. Blend a CFSAN count and a CDER count into one search term and you're averaging two different enforcement risks.

what does a fat burner letter citing a blood pressure claim tell you?

It tells you the low count for 'fat burner' already contains the exact disease-claim drift that small number appears to rule out. One of the five 'fat burner' letters — FDA's March 2, 2023 letter to Jackson Health & Wellness Clinic — quotes the brand's own ad copy: 'Regular use of Youthin Fat Burners may help control High Blood Pressure.' That sentence has nothing to do with weight; it's a hypertension claim riding inside a product the marketer chose to call a fat burner.

FDA settled this exact question in the same 2000 rulemaking that set the modern rules for supplement labeling, writing that 'elevated blood pressure (hypertension) and elevated cholesterol (hypercholesterolemia) are diseases themselves, with subsequent events (heart attack, stroke) the late consequences of those diseases.' A blood-pressure claim inside a fat-burner ad isn't a borderline case under that language — it's a disease claim wearing a metabolism-vertical name.

You cannot read the number 5 without reading what's inside it.

does a low letter count ever mean a higher claim ceiling?

No — thyroid proves the opposite, and it's the sharpest counterexample in the data. Thyroid returns only 37 letters and hypothyroidism only 10, against 146 for diabetes, yet both conditions sit under the identical, and identically strict, ceiling set by 21 CFR 101.93(g)(1). That regulation defines disease as 'damage to an organ, part, structure, or system of the body such that it does not function properly,' and an underactive thyroid gland satisfies that definition exactly the way diabetic blood sugar does. We initially treated the thyroid vertical's low letter count as a signal of looser enforcement; the regulatory text changed that reading.

Low letter volume reflects a smaller vertical, not a looser rule.

Cholesterol makes the same point from the high side. Its 105-letter count is large not because the rule is stricter than diabetes, but because FDA has said outright that elevated cholesterol is itself the disease, not a risk factor for one, which turns almost any 'lowers cholesterol' sentence into a citable claim. A high count and a low count can both sit on top of a hard ceiling; the count measures enforcement volume, and the statute sets the ceiling, not the search-hit total.

what should replace letter counts when you rank niche risk?

Read 21 CFR 101.93(g)'s ten disease-claim triggers directly, and rank a niche by which of them your creative activates, then use warning letters only to find worked examples of that trigger in the wild, never as the danger score itself. A single letter can carry more usable signal than a count of 146: FDA's letter to Lysulin shows the agency treating Instagram hashtags as drug evidence, a fact no raw count will ever surface no matter how large the number gets.

Check who issued the letter and what theory it charges before you trust any count at all. A CFSAN misbranding letter answers a different question than a CDER unapproved-drug letter, and a search-term total blends both into one number that means nothing on its own. Build your risk read from the trigger list, the issuing office, and two or three actual letters read start to finish — the count is a starting point for a search, not a conclusion you can brief off.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Meta Ad Library. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, Is Weight Loss Pills Covered by Insurance?, Do Weight Loss Clinics Offer Ozempic?, Do Weight Loss Pills from Hers Work?, Peptide Network Marketing: A Reference for Operators, and GLP-1 affiliate marketing intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.